Introduction
Long term medical therapy with antiepileptic drugs (AEDs) is detrimental for bone mineralisation. 1 There is increasing evidence suggesting that most of the old AEDs decrease bone mineral density (BMD) in adults, and there are a few and small studies on the newer ones (gabapentin, oxcarbazepin, zonisamide) (for a review see Ref.2) . Several studies suggested that treatment with lamotrigine (LTG) does not affect BMD. [3] [4] [5] There are only few and controversial data concerning the effect of levetiracetam (LEV) on BMD. In rats treatment with LEV decreased significantly the bone biomechanical strength parameters. 6 However, BMD seemed unaffected by the LEV treatment in rats. 6 One study on 16 adult patients treated with LEV did not find significant decrease in BMD. 7 Decreased BMD was found in patients treated with OXC, but both studies were on children. 8, 9 The purpose of our study was to investigate the effect of different AEDs on the bone mineralisation. We compared the incidence of reduced BMD among adult patients treated with various AEDs.
Methods
In this cross-sectional study we retrospectively analysed data from 168 adult outpatients with epilepsy treated with various AEDs for more than 2 years and who underwent measurement of BMD. Based on evidence for increased risk of decreased BMD in patients on long-term treatment with AEDs, according to the local guidelines we offer BMD measurement to all adult patients who have been treated with AEDs for more than 2 years. All patients gave their informed consent in accordance to the declaration of Helsinki. 10 The mean age was 43.3 years (range: 17-77; median:
44 years). The group comprised 65 female (39%) and 103 male (61%) patients. The patients were treated with 6 different AEDs: LTG, LEV, CBZ, OXC, VPA, and TPM. One-hundred-and-eight patients were on monotherapy, and 60 patients were on two or more AEDs. Mean duration of treatment was 14 years (range: 2-29; median: 10 years).
BMD was measured in the lumbar spine and the total hip, including femoral neck and trochanter, using a Lunar DEXAscanner (GE Healthcare, Madison, WI). T scores (number of SD below peak bone mass) were calculated. Low BMD: osteopenia (T score between À1 and À2.5 SD) and osteoporosis (T score lower than À2.5 SD) were defined according to WHO criteria.
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The incidence of patients with low BMD among the patients treated with the 6 different AEDs and the gender distribution was assessed using chi square test. The age distribution was compared among the groups using t-test. The level of statistical significance was set to 0.05.
Results
Forty-nine patients on monotherapy (45.3%) and 26 patients on polytherapy (43.3%) had decreased BMD (Table 1) . There is considerable evidence suggesting, that older antiepileptic drugs (AEDs) and some of the newer ones decrease bone mineral density (BMD). However, there is only limited and conflicting data concerning the effect of levetiracetam on BMD. In this cross-sectional study we analysed data from 168 adult consecutive outpatients treated with AEDs for more than 2 years, and who underwent measurement of the BMD. We compared the incidence of decreased BMD among the patients treated with 6 different AEDs: carbamazepine (CBZ), oxcarbazepine (OXC), valproic acid (VPA), lamotrigine (LTG), topiramate (TPM) and levetiracetam (LEV). Among the patients on monotherapy, reduced BMD was present significantly most often in patients treated with LEV and those treated with OXC. In the group of patients on polytherapy there was no significant difference in the incidence of low BMD among patients treated with various AEDs. Our data suggest that patients on long-term treatment with LEV have a higher risk for affection of bone density.
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Among patients using AEDs in monotherapy the incidence of decreased BMD was significantly higher in patients treated with LEV or with OXC as compared to the remaining patients (p < 0.05) ( Supplementary Fig. 1 ) No significant difference was found concerning age and gender between the group of patients treated with LEV or OXC and the rest of the patients (Table 2 ).
In our patients on polytherapy, we did not find significant difference between the six studied AEDs concerning the incidence of decreased BMD.
Discussion
There is increasing evidence that chronic treatment with AEDs is associated with changes in bone metabolism, increasing the risk of fractures in patients with epilepsy. AEDs are used not only in patients with epilepsy but also in increasing number of patients with other conditions (headache, neuropathic pain). 12, 13 In order to compare the effect of different AEDs on BMD, in this cross-sectional study we analysed data from 168 adult outpatients, treated with 6 different AEDs.
Concerning the effect of LEV on BMD there are only few and conflicting data reported in the literature. 6, 7 Our results suggest that LEV is more often associated with decreased BMD compared to the other AEDs, although the duration of therapy was significantly shorter (mean: 4.4 years) in the group of patients treated with LEV. Two previous studies demonstrated decreased BMD in children treated with OXC. 8, 9 Our data support that this also is the case in adult patients. Age and gender have not influenced our data significantly (se results we have described this there), thus the observed differences in the incidence of decreased BMD cannot be attributed to these factors. However, the sample size in the six groups of AEDs was not sufficient to analyse other co-founders, and further, multicentre studies are needed to fully elucidate this.
Based upon our results we suggest that BMD measurement should be considered in adult patients using also some newer AEDs, especially LEV and OXC on long-term and not only in the case of enzyme inducing drugs as suggested previously. 
